Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Announce Quarterly Sales of $2.26 Million
Equities analysts expect that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will report $2.26 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.50 million to $3.28 million. Tetraphase Pharmaceuticals reported sales of $1.09 million in the same quarter last year, which would suggest a positive year over year growth rate of 107.3%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 14th.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $2.26 million for the current fiscal year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts anticipate that the firm will report sales of $6.58 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting analysts’ consensus estimates of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% on a year-over-year basis.
In related news, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at about $195,000. California State Teachers Retirement System raised its position in shares of Tetraphase Pharmaceuticals by 20.1% during the 3rd quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 13,451 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Tetraphase Pharmaceuticals by 32.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after acquiring an additional 360,552 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Tetraphase Pharmaceuticals by 67.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 217,079 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 87,398 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Tetraphase Pharmaceuticals during the 3rd quarter worth about $7,915,000. Institutional investors and hedge funds own 58.19% of the company’s stock.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up $0.14 during trading on Friday, reaching $5.89. The company had a trading volume of 1,610,455 shares, compared to its average volume of 514,643. Tetraphase Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.93.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.